Clicky

Vaccinex, Inc.(VCNX)

Description: Vaccinex Inc. is a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics. The Company is focused on providing treatments for serious diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. It provides SEMA4D antibody platform, which is focused on developing its lead product candidate VX15/2503 (VX15) for the treatment of non-small cell lung cancer, NSCLC, osteosarcoma, melanoma and Huntington’s disease. It also provides ActiveMAb antibody discovery platform, a human antibody discovery platform used for expressing large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of vaccinia, a mammalian virus. Its product candidate VX5 is in preclinical development for the treatment of multiple sclerosis and potentially for other autoimmune disorders.


Keywords: Biotechnology Cancer Biology Immunology Immune System Antibodies Monoclonal Antibodies Antibody Clinical Development Non Small Cell Lung Cancer Melanoma Multiple Sclerosis Small Cell Lung Cancer Neurodegenerative Diseases Degenerative Disease Serious Diseases Sarcoma Treatment Of Non Small Cell Lung Cancer Nsclc Autoimmune Disorders Immune Disorders Treatment Of Multiple Sclerosis Osteosarcoma Human Monoclonal Antibodies Seth Lederman Vaccinia

Home Page: www.vaccinex.com

VCNX Technical Analysis

1895 Mount Hope Avenue
Rochester, NY 14620
United States
Phone: 585 271 2700


Officers

Name Title
Dr. Maurice Zauderer Ph.D. Co-Founder, CEO, Pres & Director
Mr. Scott E. Royer C.F.A., M.B.A. Chief Financial Officer
Dr. Ernest S. Smith Ph.D. Sr. VP of Research & Chief Scientific Officer
Dr. Elizabeth E. Evans Ph.D. COO and Sr. VP of Discovery & Translational Medicine
Dr. John E. Leonard Ph.D. Sr. VP of Devel.

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 5.5316
Price-to-Sales TTM: 699.3697
IPO Date: 2018-08-09
Fiscal Year End: December
Full Time Employees: 39
Back to stocks